Brown Mark R, Boster Joshua M, Goertzen Stephen M, Morris Michael J, Manninen Erik S
Internal Medicine, San Antonio Military Medical Center, San Antonio, USA.
Pulmonary and Critical Care Medicine, San Antonio Military Medical Center, San Antonio, USA.
Cureus. 2023 Aug 1;15(8):e42789. doi: 10.7759/cureus.42789. eCollection 2023 Aug.
A 33-year-old male with severe COVID-19 required prolonged veno-venous extracorporeal membrane oxygenation (ECMO) support. Following decannulation, he developed an empyema. Tube thoracostomy and broad-spectrum antibiotics were initiated, followed by an unsuccessful attempt at pleural irrigation with saline, given the patient had an increased risk of bleeding due to the concomitant requirement for systemic anticoagulation. Subsequently, intrapleural tissue plasminogen activator (tPA) and recombinant human Dornase alfa (DNase) were safely administered with the resolution of empyema. is an uncommon cause of pleural empyema and, to our knowledge, has not previously been reported to be associated with COVID-19 or ECMO.
一名33岁的重症新型冠状病毒肺炎男性患者需要长时间的静脉-静脉体外膜肺氧合（ECMO）支持。拔管后，他发生了脓胸。开始进行胸腔闭式引流并使用广谱抗生素，随后尝试用生理盐水进行胸腔冲洗但未成功，因为该患者因同时需要全身抗凝而出血风险增加。随后，胸腔内安全给予组织型纤溶酶原激活剂（tPA）和重组人脱氧核糖核酸酶（DNase），脓胸得以消退。 是胸膜脓胸的罕见原因，据我们所知，此前尚未报道其与新型冠状病毒肺炎或ECMO相关。 （原文此处似乎有信息缺失）
